Achievement of MMR by month 12 is directly associated with improved survival1
MMR versus >1% on the international scale at 12 months showed better Overall survival
• OS (99% [95% CI, 97% to 100%] vs 93% [95% CI, 90% to 96%]; P=0.0011) at 3 years
• No difference was observed in the group with (0.1% to <1% on the international scale; OS, 98% [95% CI, 95% to 100%])
Objective & Methods:
A German CML Study Group conducted a randomized treatment optimization trial in newly diagnosed patients with CP-CML with regard to cytogenetic and molecular remission rates, survival, and toxicity. The first primary end point was the rate of major molecular remission (MMR) at 12 months
MMR and Progression-free survival over years2
Patients who reached 0.1% BCR-ABL1IS (MMR) at 12 months had significantly better
progression-free survival than those who did not2
Adapted from ref 3
MMR, Major molecular response; OS, Overall survival; PFS, Progression free survival
References
Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-a in newly diagnosed chronic myeloid leukemia. J Clin Oncol. 2011 Apr;29(12):1634-42.
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017 Nov;31(11):2398-406.
Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. SUPPLEMENT.Leukemia. 2017 Nov;31(11):2398-406.
Approved by Egyptian Drug Authority: HF0424OA5944/042026. Invalidation date: 20/04/2028
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg
Image
HF0424OA5944/042026 20/04/2028 |